Pfizer phase 3 study of Lyrica oral solution CV in paediatric epilepsy meets primary endpoint

Pfizer Inc. announced positive topline results of a phase 3 study examining the use of Lyrica pregabalin oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patient…
Read the full story: Bioportfolio Latest News